Non-coding RNAs and Hippo signaling in non-small cell lung cancer: emerging roles as biomarkers and therapeutic targets
Related Experiment Video
Updated: Sep 8, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Mohammadamin Joulani1, Nahal Aghajamal2, Masoumeh Nouri3
1Student Research Committee, Faculty of Medicine, Iran University of Medical Sciences, Tehran, 009821, Iran.
Abstract:
The most common type of cancer and one with a high death rate is lung cancer, especially non-small cell lung cancer (NSCLC), which is mostly brought on by medication resistance, metastasis, and delayed diagnosis. The discovery of non-coding RNAs (ncRNAs), such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), has revealed their vital involvement in the pathophysiology of lung cancer by controlling important cellular processes. The Hippo signaling pathway is one of the critical routes impacted by non-coding RNAs. It is involved in tumor suppression, apoptosis, and cell proliferation. The interaction between ncRNAs and the Hippo pathway in lung cancer is reviewed in this review, with an emphasis on the potential of these molecules as therapeutic targets as well as diagnostic and prognostic biomarkers.
More Related Videos
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
Related Concept Videos
lncRNA - Long Non-coding RNAs
Hedgehog Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Non-Canonical Wnt Signaling Pathways
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...